Annovis Bio regains NYSE listing compliance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Annovis Bio Regains NYSE Listing Compliance
May 26, 2026 8:00 AM EDTMALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (Annovis or the Company), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimers disease (AD) and Parkinsons disease (PD), announced today that it has regained compliance with the New York Stock Exchange (NYSE) continued listing standards.
On March 26, 2025, the NYSE notified Annovis of its non-compliance with Section 802.01B of the NYSE Listed Company Manual, as the Company's average global market capitalization had fallen below $50 million over a consecutive 30-trading-day period while... More
